1. Scrip

Trevi Gets A Clap On The Back For Chronic Cough Data

 
• By Jessica Merrill

A Phase IIa trial studying Haduvio for the treatment of refractory chronic cough showed a benefit for patients, opening the door to a broad market and impressing investors.

(Shutterstock)
Key Takeaways
  • Trevi’s kappa agonist and mu antagonist (KAMA) Haduvio (nalbuphine ER) showed an efficacy benefit in a Phase IIa trial in refractory chronic cough (RCC).

Trevi Therapeutics succeeded in a Phase IIa trial testing the kappa agonist and mu antagonist (KAMA) Haduvio (nalbuphine ER) in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

More from Business